# Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

> **NCT02255162** · PHASE1 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Acute Myelocytic Leukemia
- Acute Myelogenous Leukemia
- Acute Granulocytic Leukemia
- Acute Non-Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **GENETIC:** HLA-mismatched stem-cell Microtransplantation
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02255162
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2017-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255162, "Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02255162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*